Cytokinetics, Incorporated $CYTK Shares Acquired by Capital International Investors

Capital International Investors increased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 0.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,178,780 shares of the biopharmaceutical company’s stock after buying an additional 10,670 shares during the period. Capital International Investors owned about 0.96% of Cytokinetics worth $64,786,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. UMB Bank n.a. raised its position in Cytokinetics by 10.6% during the third quarter. UMB Bank n.a. now owns 1,762 shares of the biopharmaceutical company’s stock worth $97,000 after acquiring an additional 169 shares during the period. Fifth Third Bancorp grew its position in shares of Cytokinetics by 32.3% in the third quarter. Fifth Third Bancorp now owns 1,072 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 262 shares during the period. Thrivent Financial for Lutherans grew its position in shares of Cytokinetics by 1.6% in the second quarter. Thrivent Financial for Lutherans now owns 28,119 shares of the biopharmaceutical company’s stock valued at $929,000 after purchasing an additional 449 shares during the period. Farther Finance Advisors LLC increased its stake in shares of Cytokinetics by 68.4% during the third quarter. Farther Finance Advisors LLC now owns 1,115 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 453 shares in the last quarter. Finally, Arizona State Retirement System increased its stake in shares of Cytokinetics by 1.6% during the third quarter. Arizona State Retirement System now owns 33,546 shares of the biopharmaceutical company’s stock worth $1,844,000 after purchasing an additional 527 shares in the last quarter.

Cytokinetics Stock Performance

Shares of Cytokinetics stock opened at $63.63 on Thursday. The stock has a 50 day moving average of $64.02 and a 200 day moving average of $60.10. The firm has a market capitalization of $7.84 billion, a price-to-earnings ratio of -9.74 and a beta of 0.56. Cytokinetics, Incorporated has a fifty-two week low of $29.31 and a fifty-two week high of $70.98.

Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.02). The business had revenue of $17.76 million during the quarter, compared to the consensus estimate of $8.02 million. During the same quarter in the prior year, the company earned ($1.26) EPS. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. Analysts forecast that Cytokinetics, Incorporated will post -5.24 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on CYTK. Barclays started coverage on shares of Cytokinetics in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $87.00 price target on the stock. The Goldman Sachs Group set a $95.00 target price on Cytokinetics and gave the company a “buy” rating in a report on Thursday, December 18th. Morgan Stanley set a $90.00 target price on Cytokinetics in a research report on Thursday, January 8th. Citigroup reaffirmed a “market outperform” rating on shares of Cytokinetics in a research note on Monday, December 22nd. Finally, JPMorgan Chase & Co. boosted their price target on Cytokinetics from $70.00 to $74.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. Seventeen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $89.00.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Earnings/investor call framed a “high‑stakes” commercial launch as Cytokinetics shifts into commercialization — investors see successful market uptake as material revenue upside. Read More.
• Positive Sentiment: An insider exercised options valued at roughly $920k+ as the drug hit the market — often read as insiders monetizing launch value and signaling commercialization is underway. Read More.
• Positive Sentiment: Analyst activity remains constructive: several firms raised price targets and some maintain buy ratings, leaving a consensus target materially above current levels — supportive for medium‑term upside.
• Neutral Sentiment: Reported short‑interest data for early March shows “0” shares and a 0.0 days ratio — this is almost certainly a data/reporting anomaly rather than a real change in short positioning; treat as non‑informative until updated.
• Negative Sentiment: Insider sales on March 9: CEO Robert I. Blum sold 7,931 shares (~$481.6k) and EVPs Fady I. Malik and Andrew Callos sold 2,907 and 2,582 shares respectively at about $60.72 — substantial executives remain holders, but these disclosures look like near‑term profit‑taking and can weigh on sentiment. SEC filings: CEO Form 4 (Read More.), Malik Form 4 (Read More.), Callos Form 4 (Read More.).

Insiders Place Their Bets

In other Cytokinetics news, EVP Fady Ibraham Malik sold 2,907 shares of the stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $60.72, for a total transaction of $176,513.04. Following the completion of the transaction, the executive vice president owned 138,629 shares of the company’s stock, valued at $8,417,552.88. This trade represents a 2.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Andrew Callos sold 2,582 shares of Cytokinetics stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $60.72, for a total transaction of $156,779.04. Following the sale, the executive vice president owned 47,858 shares of the company’s stock, valued at approximately $2,905,937.76. This represents a 5.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 96,113 shares of company stock valued at $5,994,726 over the last 90 days. Company insiders own 2.70% of the company’s stock.

Cytokinetics Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.